Novo Nordisk's US stock rose more than 8% before the market opened. Clinical trials showed that its weight loss drug Amycretin reduced body weight by 22%.

2025-01-24 18:38:33

Novo Nordisk's US stock rose more than 8% in pre-market trading. The company announced the results of a Phase 1b/2a clinical trial for Amycretin. Patients treated with Amycretin lost 9.7% of their body weight after 20 weeks, 16.2% after 28 weeks, and 22.0% after 36 weeks. Based on this result, Novo Nordisk is planning to further develop Amycretin for overweight or obese adults.

weight loss drug Novo Nordisk

Email Subscription

Newsletters and emails are now available! Delivered on time, every weekday, to keep you up to date with North American business news.

Weekly Highlights

                                    Trump says he doesn't care about bill
                            2025-11-19

                                    After $2,000 Payments, Remaining Revenue to Slash National Debt
                            2025-11-16

                                    The Financial Times has reported that Oracle's, $ORCL, $300 billion OpenAI deal is already underwater
                            2025-11-19

                                    Pam Bondi has 30 days to release the Epstein files
                            2025-11-21

                                    Larry Summers’ Epstein Email Fallout: What It Means for Markets & Trust
                            2025-11-18